MARKET

ENGNW

ENGNW

enGene Therapeutics Inc
NASDAQ
0.2101
-0.0513
-19.63%
Closed 15:56 05/15 EDT
OPEN
0.1700
PREV CLOSE
0.2614
HIGH
0.2800
LOW
0.1700
VOLUME
51.38K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.1113
MARKET CAP
--
P/E (TTM)
-0.0933
1D
5D
1M
3M
1Y
5Y
1D
enGene Holdings Is Maintained at Neutral by UBS
Dow Jones · 2d ago
enGene Holdings Price Target Cut to $2.00/Share From $9.00 by UBS
Dow Jones · 2d ago
enGene price target lowered to $2 from $9 at UBS
TipRanks · 2d ago
ENGENE THERAPEUTICS INC <ENGN.O>: UBS CUTS TARGET PRICE TO $2 FROM $9
Reuters · 2d ago
Weekly Report: what happened at ENGN last week (0504-0508)?
Weekly Report · 5d ago
enGene Therapeutics announces annual shareholder meeting webcast
PUBT · 05/08 20:08
Leerink downgraded enGene to Market Perform following LEGEND update
TipRanks · 05/08 18:32
enGene downgraded to Perform from Outperform at Oppenheimer
TipRanks · 05/08 16:22
More
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGNW stock methods without spending real money on the virtual paper trading platform.